398 related articles for article (PubMed ID: 25149081)
21. Impaired blood-brain barrier function in angiotensinogen-deficient mice.
Kakinuma Y; Hama H; Sugiyama F; Yagami K; Goto K; Murakami K; Fukamizu A
Nat Med; 1998 Sep; 4(9):1078-80. PubMed ID: 9734405
[TBL] [Abstract][Full Text] [Related]
22. Immune cell trafficking across the barriers of the central nervous system in multiple sclerosis and stroke.
Lopes Pinheiro MA; Kooij G; Mizee MR; Kamermans A; Enzmann G; Lyck R; Schwaninger M; Engelhardt B; de Vries HE
Biochim Biophys Acta; 2016 Mar; 1862(3):461-71. PubMed ID: 26527183
[TBL] [Abstract][Full Text] [Related]
23. Oligodendrocyte gap junction loss and disconnection from reactive astrocytes in multiple sclerosis gray matter.
Markoullis K; Sargiannidou I; Schiza N; Roncaroli F; Reynolds R; Kleopa KA
J Neuropathol Exp Neurol; 2014 Sep; 73(9):865-79. PubMed ID: 25101702
[TBL] [Abstract][Full Text] [Related]
24. Glial regulation of the blood-brain barrier in health and disease.
Broux B; Gowing E; Prat A
Semin Immunopathol; 2015 Nov; 37(6):577-90. PubMed ID: 26245144
[TBL] [Abstract][Full Text] [Related]
25. Gene expression analysis of the microvascular compartment in multiple sclerosis using laser microdissected blood vessels.
Cunnea P; McMahon J; O'Connell E; Mashayekhi K; Fitzgerald U; McQuaid S
Acta Neuropathol; 2010 May; 119(5):601-15. PubMed ID: 19967542
[TBL] [Abstract][Full Text] [Related]
26. Angiotensin II controls occludin function and is required for blood brain barrier maintenance: relevance to multiple sclerosis.
Wosik K; Cayrol R; Dodelet-Devillers A; Berthelet F; Bernard M; Moumdjian R; Bouthillier A; Reudelhuber TL; Prat A
J Neurosci; 2007 Aug; 27(34):9032-42. PubMed ID: 17715340
[TBL] [Abstract][Full Text] [Related]
27. MK801 blocks hypoxic blood-brain-barrier disruption and leukocyte adhesion.
Kuhlmann CR; Zehendner CM; Gerigk M; Closhen D; Bender B; Friedl P; Luhmann HJ
Neurosci Lett; 2009 Jan; 449(3):168-72. PubMed ID: 18996441
[TBL] [Abstract][Full Text] [Related]
28. In vitro and in vivo activation of astrocytes by amyloid-beta is potentiated by pro-oxidant agents.
García-Matas S; de Vera N; Aznar AO; Marimon JM; Adell A; Planas AM; Cristòfol R; Sanfeliu C
J Alzheimers Dis; 2010; 20(1):229-45. PubMed ID: 20164580
[TBL] [Abstract][Full Text] [Related]
29. Localisation of citrullinated proteins in normal appearing white matter and lesions in the central nervous system in multiple sclerosis.
Bradford CM; Ramos I; Cross AK; Haddock G; McQuaid S; Nicholas AP; Woodroofe MN
J Neuroimmunol; 2014 Aug; 273(1-2):85-95. PubMed ID: 24907905
[TBL] [Abstract][Full Text] [Related]
30. NADPH oxidase mediates TNF-α-evoked in vitro brain barrier dysfunction: roles of apoptosis and time.
Abdullah Z; Bayraktutan U
Mol Cell Neurosci; 2014 Jul; 61():72-84. PubMed ID: 24907586
[TBL] [Abstract][Full Text] [Related]
31. Metabolic gene expression changes in astrocytes in Multiple Sclerosis cerebral cortex are indicative of immune-mediated signaling.
Zeis T; Allaman I; Gentner M; Schroder K; Tschopp J; Magistretti PJ; Schaeren-Wiemers N
Brain Behav Immun; 2015 Aug; 48():313-25. PubMed ID: 25937052
[TBL] [Abstract][Full Text] [Related]
32. Role of the blood-brain barrier in multiple sclerosis.
Ortiz GG; Pacheco-Moisés FP; Macías-Islas MÁ; Flores-Alvarado LJ; Mireles-Ramírez MA; González-Renovato ED; Hernández-Navarro VE; Sánchez-López AL; Alatorre-Jiménez MA
Arch Med Res; 2014 Nov; 45(8):687-97. PubMed ID: 25431839
[TBL] [Abstract][Full Text] [Related]
33. Anti-inflammatory effect of retinoic acid on prostaglandin synthesis in cultured cortical astrocytes.
Kampmann E; Johann S; van Neerven S; Beyer C; Mey J
J Neurochem; 2008 Jul; 106(1):320-32. PubMed ID: 18394023
[TBL] [Abstract][Full Text] [Related]
34. Expression of MCP-1 by reactive astrocytes in demyelinating multiple sclerosis lesions.
Van Der Voorn P; Tekstra J; Beelen RH; Tensen CP; Van Der Valk P; De Groot CJ
Am J Pathol; 1999 Jan; 154(1):45-51. PubMed ID: 9916917
[TBL] [Abstract][Full Text] [Related]
35. Blood-brain barrier hyperpermeability precedes demyelination in the cuprizone model.
Berghoff SA; Düking T; Spieth L; Winchenbach J; Stumpf SK; Gerndt N; Kusch K; Ruhwedel T; Möbius W; Saher G
Acta Neuropathol Commun; 2017 Dec; 5(1):94. PubMed ID: 29195512
[TBL] [Abstract][Full Text] [Related]
36. How do immune cells overcome the blood-brain barrier in multiple sclerosis?
Larochelle C; Alvarez JI; Prat A
FEBS Lett; 2011 Dec; 585(23):3770-80. PubMed ID: 21550344
[TBL] [Abstract][Full Text] [Related]
37. Differential loss of KIR4.1 immunoreactivity in multiple sclerosis lesions.
Schirmer L; Srivastava R; Kalluri SR; Böttinger S; Herwerth M; Carassiti D; Srivastava B; Gempt J; Schlegel J; Kuhlmann T; Korn T; Reynolds R; Hemmer B
Ann Neurol; 2014 Jun; 75(6):810-28. PubMed ID: 24777949
[TBL] [Abstract][Full Text] [Related]
38. Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression.
van Horssen J; Schreibelt G; Drexhage J; Hazes T; Dijkstra CD; van der Valk P; de Vries HE
Free Radic Biol Med; 2008 Dec; 45(12):1729-37. PubMed ID: 18930811
[TBL] [Abstract][Full Text] [Related]
39. Small heat shock proteins are induced during multiple sclerosis lesion development in white but not grey matter.
Peferoen LA; Gerritsen WH; Breur M; Ummenthum KM; Peferoen-Baert RM; van der Valk P; van Noort JM; Amor S
Acta Neuropathol Commun; 2015 Dec; 3():87. PubMed ID: 26694816
[TBL] [Abstract][Full Text] [Related]
40. The effects of blood-brain barrier disruption on glial cell function in multiple sclerosis.
McQuaid S; Cunnea P; McMahon J; Fitzgerald U
Biochem Soc Trans; 2009 Feb; 37(Pt 1):329-31. PubMed ID: 19143657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
